PCSA
Income statement / Annual
Last year (2024), Processa Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Processa Pharmaceuticals, Inc.'s net income was -$11.85 M.
See Processa Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$5.00 K |
$113.43 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$882.06 K
|
$0.00
|
$0.00
|
$0.00
|
$1.38 K
|
$125.88 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$882.06 K
|
-$877.90 K
|
-$630.09 K
|
-$1.87 K
|
$3.62 K
|
-$12.45 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.72
|
-0.11
|
| Research and Development Expenses |
$7.27 M
|
$5.80 M
|
$11.49 M
|
$6.88 M
|
$11.08 M
|
$2.32 M
|
$3.09 M
|
$926.12 K
|
$6.56 K
|
$29.25 K
|
| General & Administrative Expenses |
$4.78 M
|
$5.66 M
|
$8.76 M
|
$4.69 M
|
$0.00
|
$1.61 M
|
$1.44 M
|
$876.32 K
|
$384.52 K
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.78 M
|
$5.66 M
|
$8.76 M
|
$4.69 M
|
$3.18 M
|
$1.61 M
|
$1.44 M
|
$876.32 K
|
$384.52 K
|
$945.46 K
|
| Other Expenses |
$0.00
|
$0.00
|
$7.27 M
|
$566.58 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.85 M
|
$0.00
|
| Operating Expenses |
$12.05 M
|
$11.46 M
|
$27.53 M
|
$12.13 M
|
$14.25 M
|
$3.94 M
|
$4.52 M
|
$1.80 M
|
$1.93 M
|
$974.71 K
|
| Cost And Expenses |
$12.05 M
|
$11.46 M
|
$27.53 M
|
$12.13 M
|
$15.14 M
|
$3.94 M
|
$4.52 M
|
$1.80 M
|
$76.53 K
|
$1.10 M
|
| Interest Income |
$201.09 K
|
$335.54 K
|
$101.20 K
|
$11.99 K
|
$3.17 K
|
$11.55 K
|
$18.30 K
|
$5.18 K
|
$0.00
|
$4.65 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$362.00
|
$281.12 K
|
$36.66 K
|
$161.21 K
|
$35.69 K
|
$245.38 K
|
$235.64 K
|
| Depreciation & Amortization |
$782.00
|
$222.00
|
$788.50 K
|
$790.97 K
|
$882.06 K
|
$877.90 K
|
$630.09 K
|
$1.87 K
|
$1.38 K
|
$238.82 K
|
| EBITDA |
-$12.05 M |
-$11.46 M |
-$19.47 M |
-$10.78 M |
-$14.25 M |
-$3.05 M |
-$3.88 M |
-$1.80 M |
-$337.18 K |
-$2.51 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-67.44
|
-22.11
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-384.3
|
23.73
|
| Total Other Income/Expenses Net |
$201.09 K
|
$335.54 K
|
$101.20 K
|
$175.40 K
|
-$277.95 K
|
-$25.11 K
|
-$142.91 K
|
-$53.88 K
|
$4.45 K
|
-$5.67 M
|
| Income Before Tax |
-$11.85 M
|
-$11.12 M
|
-$27.42 M
|
-$11.96 M
|
-$15.41 M
|
-$3.96 M
|
-$4.67 M
|
-$1.86 M
|
-$337.18 K
|
-$2.98 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-67.44
|
-26.3
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
-$530.61 K
|
-$1.00 M
|
-$602.72 K
|
-$902.80 K
|
-$18.19 K
|
-$1.20 K
|
$100.00
|
| Net Income |
-$11.85 M
|
-$11.12 M
|
-$27.42 M
|
-$11.43 M
|
-$19.04 M
|
-$3.36 M
|
-$3.77 M
|
-$1.86 M
|
-$335.98 K
|
-$3.35 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-67.2
|
-29.57
|
| EPS |
-3.87 |
-8.48 |
-1.7 |
-14.92 |
-50.77 |
-12.17 |
-14.2 |
-8 |
-29.89 |
-298.4 |
| EPS Diluted |
-3.87 |
-8.48 |
-1.7 |
-14.92 |
-50.77 |
-12.17 |
-14.2 |
-8 |
-29.89 |
-298.4 |
| Weighted Average Shares Out |
$3.06 M
|
$1.31 M
|
$16.11 M
|
$765.97 K
|
$374.98 K
|
$275.87 K
|
$266.61 K
|
$232.83 K
|
$11.24 K
|
$11.24 K
|
| Weighted Average Shares Out Diluted |
$3.06 M
|
$1.31 M
|
$16.11 M
|
$765.97 K
|
$374.98 K
|
$275.87 K
|
$266.61 K
|
$232.83 K
|
$11.24 K
|
$11.24 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
